Anticraving medications for relapse prevention: a possible new class of psychoactive medications
- PMID: 16055763
- DOI: 10.1176/appi.ajp.162.8.1423
Anticraving medications for relapse prevention: a possible new class of psychoactive medications
Abstract
Psychiatrists have gradually developed a list of medications that are effective in the treatment of addictive disorders. Although alcoholism has received the most attention, nicotine, heroin, and cocaine have all been shown to be influenced by heredity. Of course, the immediate goal is the reduction of drug craving and the prevention of relapse to compulsive drug taking. A medication that can aid in the maintenance of the opiate-free state is naltrexone, a specific opiate antagonist. Naltrexone is also a good example of an anticraving medication used in the treatment of alcoholism. Clinicians currently have two types of medication to aid in the treatment of tobacco use disorder, arguably the most important addiction. Bupropion and nicotine replacement can be given in a coordinated fashion to provide the best available results. At present, no medication is approved by the Food and Drug Administration for the indication of cocaine addiction. Recently, however, five different medications, already approved for other purposes, have been found to be effective among cocaine addicts. Despite clinical trials that show benefit, anticraving medications are not well known and are underused by clinicians. Addiction is a heterogeneous condition, with variability in reactivity to the drug of abuse and to the medications available to treat it. Recent developments in pharmacogenetics may result in improved selection of medications based on genotype.
Comment in
-
Euphorigenic and abusive properties of modafinil.Am J Psychiatry. 2006 Mar;163(3):549. doi: 10.1176/appi.ajp.163.3.549. Am J Psychiatry. 2006. PMID: 16513889 No abstract available.
Similar articles
-
Medications for substance use disorders.Soc Work Public Health. 2013;28(3-4):264-78. doi: 10.1080/19371918.2013.759031. Soc Work Public Health. 2013. PMID: 23731419 Free PMC article. Review.
-
Pharmacotherapy of addictive disorders.Clin Neuropharmacol. 2009 Sep-Oct;32(5):277-89. doi: 10.1097/wnf.0b013e3181a91655. Clin Neuropharmacol. 2009. PMID: 19834993 Review.
-
[Pharmacological relapse prevention in alcohol and tobacco dependence].Internist (Berl). 2007 Jan;48(1):79-84, 86-8. doi: 10.1007/s00108-006-1755-z. Internist (Berl). 2007. PMID: 17122900 Review. German.
-
Novel pharmacotherapeutic approaches for the treatment of drug addiction and craving.Curr Opin Pharmacol. 2005 Feb;5(1):107-18. doi: 10.1016/j.coph.2004.08.013. Curr Opin Pharmacol. 2005. PMID: 15661634 Review.
-
Pharmacologic management of relapse prevention in addictive disorders.Psychiatr Clin North Am. 2004 Dec;27(4):627-48. doi: 10.1016/j.psc.2004.06.002. Psychiatr Clin North Am. 2004. PMID: 15550284 Review.
Cited by
-
PET imaging of dopamine transporters and D2/D3 receptors in female monkeys: effects of chronic cocaine self-administration.Neuropsychopharmacology. 2023 Sep;48(10):1436-1445. doi: 10.1038/s41386-023-01622-3. Epub 2023 Jun 22. Neuropsychopharmacology. 2023. PMID: 37349473
-
The Craving-Manager smartphone app designed to diagnose substance use/addictive disorders, and manage craving and individual predictors of relapse: a study protocol for a multicenter randomized controlled trial.Front Psychiatry. 2023 May 15;14:1143167. doi: 10.3389/fpsyt.2023.1143167. eCollection 2023. Front Psychiatry. 2023. PMID: 37255691 Free PMC article.
-
Shared Mechanisms of GABAergic and Opioidergic Transmission Regulate Corticolimbic Reward Systems and Cognitive Aspects of Motivational Behaviors.Brain Sci. 2023 May 17;13(5):815. doi: 10.3390/brainsci13050815. Brain Sci. 2023. PMID: 37239287 Free PMC article. Review.
-
Cocaine-Induced Time-Dependent Alterations in Cytochrome P450 and Liver Function.Int J Mol Sci. 2023 Jan 13;24(2):1632. doi: 10.3390/ijms24021632. Int J Mol Sci. 2023. PMID: 36675146 Free PMC article. Review.
-
VR for Studying the Neuroscience of Emotional Responses.Curr Top Behav Neurosci. 2023;65:161-187. doi: 10.1007/7854_2022_405. Curr Top Behav Neurosci. 2023. PMID: 36592276
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical